News & Updates
On December 1, Shenzhen Mindray Bio-Medical Electronics Co., Ltd announced complete acquisition of 75% stake in Germany based DiaSys Diagnostics Systems GmbH. DiaSys is now recognized as a majority-owned Mindray subsidiary.
In line with the slogan "Where healthcare is going", the entire world of medicine will come together once again at one of the largest global trade fairs in Düsseldorf from November 13 to 16, 2023.
DiaSys and Hytest cordially invite you to register for a joined webinar on PCT.
PCT is an established biomarker used to guide antibiotic treatment in septic patients. As an invaluable indicator, it shows high sensitivity and specificity for bacterial infection. Variability in results from different commercial assays has been observed in the use of PCT in the clinical setting.
In this webinar, participants will have the opportunity to review the clinical application of PCT, technology used for PCT measurements and the challenges in terms of the standardization effort.
EVENT DATE & TIME
September 20, 2023 16:00pm (CET), 10:00am (EDT), 7:00am (PDT)
Annually, the AACC provides laboratory medicine professionals the opportunity to connect with global leaders in laboratory medicine and to learn about the latest innovations
The shareholders of DiaSys Group, with its registered headquarter in Holzheim, community of Diez, have entered into an agreement with the Dutch subsidiary of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray), by which Mindray acquires 75% of the shares in DiaSys. This agreement is expected to be consummated later this year, following the completion of further actions and the granting of regulatory approvals.
DiaSys India has been represented at the 48th annual conference of ACBICON (Association of Clinical Biochemists of India) which took place from November 23 through 26 in New Delhi where DiaSys proudly invited visitors to learn more on their latest product innovations.
After two years of successful marketing of Procalcitonin FS, dedicated kits are now available for DiaSys respons® systems and BioMajesty® JCA-BM6010/C.
DiaSys is pleased to announce that our Total bile acids 21 FS test, which was introduced in October 2019, is from now on applicable for total bile acids (TBA) determination in human stool samples.